Sera Prognostics, Inc. (SERA) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 Salt Lake City, UT, 미국. 현재 CEO는 Zhenya Lindgardt.
SERA 을(를) 보유 IPO 날짜 2021-07-15, 63 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $81.7M.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
